An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Paitients With EGFR Mutation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2017
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Zhejiang Betta Pharma
- 05 Sep 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified sep 2015).
- 07 Jun 2016 Results analyzing efficacy and safety of icotinib presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 05 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016 as per ClinicalTrials.gov record.